Dasatinib

For research use only.

Catalog No.S1021 Synonyms: BMS-354825

277 publications

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 140 In stock
USD 147 In stock
USD 370 In stock
USD 597 In stock
USD 670 In stock
USD 817 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dasatinib has been cited by 277 publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG3NkBp M1jQRmROW09? M4DlSWlEPTB;MD6wNFAxPyEQvF2= NG[zWmUyPzl3NkC4NC=>
K562 NGD2OphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC3NkBp M336R2ROW09? MkjZTWM2OD1yLkCwNUDPxE1? NGfRSI0yPzl3NkC4NC=>
M07e MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLRZXQ6PzJiaB?= NHfyRZNFVVOR NFm2OGNKSzVyPUCuNFAyOiEQvF2= MYKxO|k2PjB6MB?=
ALL3 M{LOXWN6fG:2b4jpZ{BCe3OjeR?= M1jWOFAvOc7:TR?= MYi3NkBp NYLESWs2TE2VTx?= Mk\WTWM2OD1yLkCwNFQh|ryP MUWxPVg5QTV2MB?=
CML M4nPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DaO|IxKG2rbh?= NWO0VHlNTE2VTx?= NEDpS5JKSzVyPUCuNFAyKM7:TR?= M4XkRlE6OjF7MEG2
BA/F3 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnlPHhOPzJiaB?= MYfEUXNQ NXTSVJpRUUN3ME22MlU5QSEQvF2= MlvpNlMxQDh4NES=
BA/F3 NYjhfVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD1O|IhcA>? NV\qTZc4TE2VTx?= MUTJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= M12xbFI{ODh6NkS0
BA/F3 NGH2fnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjZO|IhcA>? MVLEUXNQ NX3lTWpRUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= MlXkNlMxQDh4NES=
BA/F3 NVzUXlBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTEO|IhcA>? MYfEUXNQ Mlm4TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP MWmyN|A5QDZ2NB?=
BA/F3 NUPXfFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[3O|IhcA>? NUHDS4h{TE2VTx?= MnH3TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? MnvUNlM{ODF5MEO=
BA/F3 NX3zRlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfmO|IhcA>? MVfEUXNQ NVrWSWFGUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2= MUGyN|MxOTdyMx?=
BA/F3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HtclczKGh? M2naT2ROW09? M2XoRmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP MWWyN|MxOTdyMx?=
BA/F3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrkZXRnPzJiaB?= M3W1fmROW09? MmPBTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? MYmyN|MxOTdyMx?=
BA/F3 NYS3UZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33PflczKGh? MmPRSG1UVw>? Mnu3TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1? M2r2ZVI{OzBzN{Cz
BA/F3 M1e3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWK3NkBp NEP2TFBFVVOR NHTSTopKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? M3j3d|I{OzBzN{Cz
BA/F3 NITCWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPUO|IhcA>? NEf5bppFVVOR MonVTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? NW\a[WtnOjN|MEG3NFM>
BA/F3 NUTWN5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWeyRXN7PzJiaB?= M1zvfmROW09? NWLVcHpkUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1? MkLyNlM{ODF5MEO=
BA/F3 NFzxNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrZSXFHPzJiaB?= NE\SOmlFVVOR NF\BNFdKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= M4HUflI{OzBzN{Cz
T cell M1\1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX23NkBp M2TtbmROW09? M2XySmlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO MUKxO|E2PDVzMh?=
WiDr NHW0bolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfEO|IhcA>? M4S1d2ROW09? MkLLTWM2OD1yLkC1NkDPxE1? MljFNVU3OTV3MUK=
PC3 NWLHXYZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfMc4Y4OiCq NY\CRoxDTE2VTx?= MonFTWM2OD1yLkCwPVQh|ryP M2\QT|E2PjF3NUGy
MDA-MB-231 Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO3NkBp M3XySGROW09? NEKwUXFKSzVyPUCuNFEzKM7:TR?= MYixOVYyPTVzMh?=
Hs578T NUXUfmMxS3m2b4TvfIlkKEG|c3H5 M3XYVVczKGh? NHPjWVJFVVOR M2\YfmdKPTB;MD6wN{DPxE1? MVuyOFAyPTN{Nx?=
HMEC NIX6UFREgXSxdH;4bYMhSXO|YYm= NF34fYc4OiCq MUPEUXNQ MYTHTVUxRTFwODFOwG0> MXGyOFAyPTN{Nx?=
DU145 M1r6PWN6fG:2b4jpZ{BCe3OjeR?= NIO4W|A4OiCq Ml3zSG1UVw>? MonOS2k2OD1yLkG2JO69VQ>? MkHINlQxOTV|Mke=
U251 MnTsR5l1d3SxeHnjJGF{e2G7 NVrZNmlJPzJiaB?= NVfJeWI4TE2VTx?= M1yzZ2dKPTB;Mj64NUDPxE1? M{G0O|I1ODF3M{K3
NCI60 MYrDfZRwfG:6aXOgRZN{[Xl? MVG3NkBp Ml\aSG1UVw>? MlrDS2k2OD13Lkeg{txO NFLTNZQzPDBzNUOyOy=>
MALME-3M M1LEXGN6fG:2b4jpZ{BCe3OjeR?= NF[xb5Q4OiCq NWrldGg3TE2VTx?= NFq2RVhIUTVyPU[uOlEh|ryP NX21WIwyOjRyMUWzNlc>
KM12 MX7DfZRwfG:6aXOgRZN{[Xl? NULqe41TPzJiaB?= NGXmfGRFVVOR NGTRS|FIUTVyPUeuOFQh|ryP MVGyOFAyPTN{Nx?=
SW620 NUn3NYZxS3m2b4TvfIlkKEG|c3H5 NF:3XW84OiCq NEPUSm5FVVOR Mlv4S2k2OD16LkSzJO69VQ>? MnvDNlQxOTV|Mke=
RXF 393NL MXvDfZRwfG:6aXOgRZN{[Xl? NI\PN|M1KGSjeYO= NHTxcG5FVVOR MUDJR|UxRTBwMEKxO{DPxE1? NXraU25NOjN{NUOwO|Q>
LXFA 983L Mlu3R5l1d3SxeHnjJGF{e2G7 NXPFWYx1PCCmYYnz MlntSG1UVw>? M3nZdGlEPTB;MD6wOVY2KM7:TR?= NHPwWYMzOzJ3M{C3OC=>
PRXF DU145 M4TzcmN6fG:2b4jpZ{BCe3OjeR?= M33IeVQh\GG7cx?= NWPveVBRTE2VTx?= M2fxb2lEPTB;MD6wOlI{KM7:TR?= Mly1NlMzPTNyN{S=
PAXF 1657L NFPNXGhEgXSxdH;4bYMhSXO|YYm= NGLiemg1KGSjeYO= M4LlfWROW09? MVrJR|UxRTBwMUKxJO69VQ>? MXOyN|I2OzB5NB?=
CXF 1103L MoWwR5l1d3SxeHnjJGF{e2G7 Mm\wOEBl[Xm| M4TBdGROW09? NWTEUXZnUUN3ME20MlM3KM7:TR?= M{PXflI{OjV|MEe0
GXF251L MVzDfZRwfG:6aXOgRZN{[Xl? MlT2OEBl[Xm| MVrEUXNQ MoHLTWM2OD1{LkK1JO69VQ>? NFTOS48zOzJ3M{C3OC=>
NCI-H23 NWezcFBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zCb|czKGh? M1LLOWROW09? M4\4TmlEPTB;Mj6yO{DPxE1? NFza[YQzOzV{MUCyNC=>
HCT116 NULuTXVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnxPWRnPzJiaB?= MlnxSG1UVw>? NYX1SmtZUUN3ME2yMlMh|ryP Ml;XNlM2OjFyMkC=
MCF7 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS3NkBp NWXScItXTE2VTx?= M2LBVGlEPTB;Mj61O{DPxE1? MoTaNlM2OjFyMkC=
NCI-H460 M{TRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYC3NkBp NHPrfphFVVOR MYPJR|UxRThwOUmg{txO MYWyN|UzOTB{MB?=
DLD1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHNO|IhcA>? NFfTV3lFVVOR MkHJTWM2OD12Lk[g{txO NWnLfoxkOjN3Nke5OlA>
NCI-H661 NVv0ZmhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;VU|czKGh? MoHjSG1UVw>? MXfJR|UxRTdwODFOwG0> NXzGV201OjN3Nke5OlA>
A549 Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSwfWF7PzJiaB?= MoThSG1UVw>? M{fLUGlEPTB;OD6yJO69VQ>? NELHd20zOzV4N{m2NC=>
U937 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorlO|IhcA>? MYrEUXNQ MoC5TWM2OD1zMj6yJO69VQ>? NHvvcoEzOzV4N{m2NC=>
HEK293 NULsUG0xTnWwY4Tpc44hSXO|YYm= MoGxNVDDqM7:TR?= M{fENGROW09? NET1ZZFKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=> NWPzWXljOjJ5N{C2NVA>
HUVEC M1;CV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn3RZBjOC5zNdMg{txO M2HDdVczKGh? NXi3OIF1TE2VTx?= NWXHOFJXUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO MV:yNlg2Ozl7Mx?=
HUVEC MYjGeY5kfGmxbjDBd5NigQ>? MljSNVXDqM7:TR?= MWS3NkBp MUfEUXNQ MUDJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> M1\KV|IzQDV|OUmz
Plasmodium falciparum M1vtZmZ2dmO2aX;uJGF{e2G7 NHnKeGMyOMLizszN NHTsVpEyPSCvaX6= M3jCc2ROW09? M3HvOGlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? M{nFdFI1PTVyM{Ow
PC3 M2ntb2Z2dmO2aX;uJGF{e2G7 Mmr2NE4yKM7:TR?= NYG5V4RSPSCq MoP1SG1UVw>? MWTJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1? NYjUPJJzOTl2NkK5O|U>
DU145 NY\5fGRDTnWwY4Tpc44hSXO|YYm= NF:0eVMxNjFizszN NWjW[pZKPSCq MnnSSG1UVw>? MV;Jcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= NVvReWNqOTl2NkK5O|U>
PC3 NFWzV3lMcW6jc3WgRZN{[Xl? MXOwMlEh|ryP MYO1JIg> MWPEUXNQ NF;TPWhKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N MVOxPVQ3Ojl5NR?=
DU145 NV7LN2JkU2mwYYPlJGF{e2G7 MnzwNE4yKM7:TR?= NUTZbWg6PSCq MkXUSG1UVw>? MnrETY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N M2jMPFE6PDZ{OUe1
PC3 NEOyRYtMcW6jc3WgRZN{[Xl? NUXmd4loOC5zIN88US=> M4HYN|UhcA>? MXrEUXNQ MUfJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> M4TBVFE6PDZ{OUe1
DU145 NHTFOWNMcW6jc3WgRZN{[Xl? M33KXVAvOSEQvF2= M{DmOFUhcA>? MoS5SG1UVw>? NEDCbXZKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= NVHhUZcyOTl2NkK5O|U>
Huh7 MV\BcpRqfmm{YXygRZN{[Xl? Mn;QNk42KM7:TR?= NVHyO49sPCCmYYnz M3fvfWROW09? NXr6RlNZUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN Moq3NVc{PjB4N{[=
C6/36 MmPkRY51cX[rcnHsJGF{e2G7 M4XkelIvPSEQvF2= NFm2WJU1KGSjeYO= MnfkSG1UVw>? Mmf6TY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>? NVXHS2JDOTd|NkC2O|Y>
U937 M2TMemZ2dmO2aX;uJGF{e2G7 NVzXPXJ[OSEQvF2= NUf5bXRSOSCq M3\HbmROW09? MWrS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? NYjtNVhZOTd4OESwPVk>
U937 NFKwW3RHfW6ldHnvckBCe3OjeR?= NEjPWI4yKM7:TR?= MXGxJIg> NF;yTG5FVVOR M2LoPXJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ MlX3NVc3QDRyOUm=
murine mast cell MXnGeY5kfGmxbjDBd5NigQ>? MYSxJO69VQ>? NIfpdpozPCCq NYTKc|ZUTE2VTx?= NXPDNYUyUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2= MoTFNVc3QDRyOUm=
BV-173 MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXoTWM2OD1yLkCwNFAxODFyOTFOwG0> M4DOV3NCVkeHUh?=
K-562 NVLQVVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTLTWM2OD1yLkCwNFAxODJ4NjFOwG0> NITtT4ZUSU6JRWK=
BL-70 NIXLcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHCZ45KSzVyPUCuNFAxODByOEKyJO69VQ>? M{nENXNCVkeHUh?=
EM-2 NXPyXIYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfQSJJKSzVyPUCuNFAxODBzMEig{txO MlrZV2FPT0WU
LAMA-84 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M336V2lEPTB;MD6wNFAxODN{MTFOwG0> NV7rflBbW0GQR1XS
MEG-01 NYGxU3oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMECwNFA6QCEQvF2= NEmzTYtUSU6JRWK=
EoL-1-cell MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf1fpgzUUN3ME2wMlAxODBzM{Gg{txO Ml\3V2FPT0WU
CTV-1 MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMECwNFQxPCEQvF2= M164THNCVkeHUh?=
TE-15 M{\sWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfIdlczUUN3ME2wMlAxPTh7IN88US=> MkewV2FPT0WU
NOS-1 NFfhOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGwVZFKSzVyPUCuNFA3OTNizszN NFzIV25USU6JRWK=
D-336MG MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEC2N{DPxE1? M3PRPXNCVkeHUh?=
LB1047-RCC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr5OHRLUUN3ME2wMlAxQTh7IN88US=> NV;EPFUyW0GQR1XS
LB996-RCC MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDX[HNGUUN3ME2wMlAxQTlzIN88US=> M1;o[XNCVkeHUh?=
SW982 M4CxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDNOVlZUUN3ME2wMlAyOTF3IN88US=> MXnTRW5ITVJ?
TK10 MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf2WlJKSzVyPUCuNFEyPzRizszN NWC2c5VzW0GQR1XS
A704 NED1dlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm2[nNKSzVyPUCuNFE1QTFizszN MYrTRW5ITVJ?
TE-8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLpXHhKSzVyPUCuNFE2PzZizszN NUnVeldZW0GQR1XS
DOHH-2 MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NViyT41GUUN3ME2wMlAyPzF7IN88US=> M2\tU3NCVkeHUh?=
HOP-62 NHLBUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fkNWlEPTB;MD6wNVg{PCEQvF2= MVPTRW5ITVJ?
TE-12 M1jmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC5ZYpKSzVyPUCuNFE5PjFizszN NWLR[XUxW0GQR1XS
KGN NX;hboxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi0Z5ZRUUN3ME2wMlAyQTR{IN88US=> M4\EWXNCVkeHUh?=
NCI-H1648 NF33e|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTITWM2OD1yLkCyNFEyKM7:TR?= MlvZV2FPT0WU
OS-RC-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMEKwN{DPxE1? NETwNG1USU6JRWK=
GB-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H2fmlEPTB;MD6wNlE2PyEQvF2= M3L6U3NCVkeHUh?=
RXF393 NImzOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEKzOVch|ryP M1npbnNCVkeHUh?=
LC-2-ad Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DsVmlEPTB;MD6wNlU5PiEQvF2= M{\rbHNCVkeHUh?=
KS-1 NHexV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHwUFZKSzVyPUCuNFI4OyEQvF2= MkPxV2FPT0WU
ETK-1 NXr3fItQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP5ZpBmUUN3ME2wMlAzQDN{IN88US=> MYjTRW5ITVJ?
SW954 NWfhUFk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;OS4RKSzVyPUCuNFI6OjdizszN MXHTRW5ITVJ?
Becker MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqwTWM2OD1yLkCzNFA{KM7:TR?= M3jWWnNCVkeHUh?=
MZ1-PC NUiz[ZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TVdGlEPTB;MD6wN|EyQSEQvF2= MX7TRW5ITVJ?
ES6 NVPxeIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHJSZJKSzVyPUCuNFMyQTNizszN NGnnbnBUSU6JRWK=
KURAMOCHI M2LIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEO0PFch|ryP MYrTRW5ITVJ?
CGTH-W-1 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn5TWM2OD1yLkCzOVQ5KM7:TR?= M2HXbXNCVkeHUh?=
VA-ES-BJ M2K5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLFTWM2OD1yLkCzPVAzKM7:TR?= NV21eGhTW0GQR1XS
LXF-289 M2r5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vRNmlEPTB;MD6wN|k2PiEQvF2= M3:wSHNCVkeHUh?=
MPP-89 NXTJbZdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHCZ|VKSzVyPUCuNFQxPDlizszN MoXJV2FPT0WU
SW872 M3vmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi2OI1pUUN3ME2wMlA1OTZzIN88US=> M3H3OXNCVkeHUh?=
SNB75 NFn1XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMES0N|Uh|ryP MlP0V2FPT0WU
PSN1 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMES0O|Qh|ryP NFLrV4FUSU6JRWK=
LB831-BLC NVzsfYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrhTWM2OD1yLkC0OlA6KM7:TR?= NYmwNVhEW0GQR1XS
MFH-ino MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HSPWlEPTB;MD6wOFczPCEQvF2= M1m0enNCVkeHUh?=
TGBC24TKB NYrWclQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr6N2NkUUN3ME2wMlA1PzZzIN88US=> M1TLTHNCVkeHUh?=
A388 NULqbY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3jV2NEUUN3ME2wMlA2ODl3IN88US=> NYK0c3BIW0GQR1XS
BB30-HNC NYfSfVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfNOGxoUUN3ME2wMlA2PDN5IN88US=> M2nSeHNCVkeHUh?=
GI-ME-N NWTENoh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwME[xNVgh|ryP M37yc3NCVkeHUh?=
TGBC1TKB MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW1TWM2OD1yLkC2NVY1KM7:TR?= MUHTRW5ITVJ?
TE-10 M{TSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3RpRKSzVyPUCuNFY{PTdizszN MV\TRW5ITVJ?
A498 NWXwTIZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEeyPFQh|ryP MkfUV2FPT0WU
TE-11 NUL2Upc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEe4OVgh|ryP M{jxenNCVkeHUh?=
BB65-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMEiyNlch|ryP MkLYV2FPT0WU
C2BBe1 NWrrW3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Hx[WlEPTB;MD6wPFMxQCEQvF2= NHf3d|JUSU6JRWK=
NCI-H747 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMEizOlIh|ryP NFS2PIxUSU6JRWK=
IST-MES1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKyTWM2OD1yLkC4OVUzKM7:TR?= NGHVTZBUSU6JRWK=
KALS-1 NIHEepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrrTWM2OD1yLkC5OFkh|ryP NHfPN25USU6JRWK=
GCIY M2XUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXITWM2OD1yLkC5OlU3KM7:TR?= MYPTRW5ITVJ?
RL95-2 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMUCzPEDPxE1? MYnTRW5ITVJ?
TE-1 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXtVZllUUN3ME2wMlExPTRizszN NEHXeZNUSU6JRWK=
NCI-H1355 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrs[pV7UUN3ME2wMlEyODJ6IN88US=> MnnXV2FPT0WU
SW962 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17tR2lEPTB;MD6xNVI6OiEQvF2= MnrOV2FPT0WU
KLE NYTCblFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrmOIFKSzVyPUCuNVE{OTdizszN MmnkV2FPT0WU
MC116 NVzSXHhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfGTWM2OD1yLkGxOFEh|ryP MUHTRW5ITVJ?
NMC-G1 MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jzWGlEPTB;MD6xNVYxPiEQvF2= NGK3Xo9USU6JRWK=
KU812 NFvSd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf5TWM2OD1yLkGxPFg{KM7:TR?= NX7rPYdFW0GQR1XS
COLO-829 NIPBN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfJS4tuUUN3ME2wMlEzOjF|IN88US=> NWDD[Y9bW0GQR1XS
NTERA-S-cl-D1 NXfiZndZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfPcphJUUN3ME2wMlEzOjh|IN88US=> MWjTRW5ITVJ?
IST-MEL1 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMUO0OUDPxE1? MlH5V2FPT0WU
MLMA M1rLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMUSwN|Ih|ryP M3TWNHNCVkeHUh?=
LS-123 NEfRfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrhW4dYUUN3ME2wMlE1ODZ2IN88US=> NYjpOlNXW0GQR1XS
LB2518-MEL NIC2[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnHNlNHUUN3ME2wMlE1OTZ{IN88US=> MXjTRW5ITVJ?
NB69 NFfiZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUS0N|Yh|ryP MlG5V2FPT0WU
8-MG-BA MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe4TWM2OD1yLkG1OFU5KM7:TR?= NYG1XHExW0GQR1XS
K5 M4LCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjSTWM2OD1yLkG2OFg6KM7:TR?= MYHTRW5ITVJ?
KINGS-1 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\hUWRKSzVyPUCuNVY3PjZizszN MknkV2FPT0WU
SF268 M4PKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvhR2hFUUN3ME2wMlE4PDB2IN88US=> NGCxflhUSU6JRWK=
PF-382 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7re2lKSzVyPUCuNVc3PzhizszN M4qxbnNCVkeHUh?=
SH-4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;kbmV3UUN3ME2wMlE5PDF|IN88US=> MYfTRW5ITVJ?
NALM-6 NXnrU5dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TpZWlEPTB;MD6xPVI6PSEQvF2= Ml\3V2FPT0WU
CP66-MEL MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHvXIoxUUN3ME2wMlE6PTNzIN88US=> NH;scXFUSU6JRWK=
697 M4L1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi1R|ZzUUN3ME2wMlE6QTh5IN88US=> MmruV2FPT0WU
CP67-MEL M1zHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;GcVFKSzVyPUCuNlA1QDhizszN NXPIfnplW0GQR1XS
DSH1 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG4TWM2OD1yLkK0NFAyKM7:TR?= MnjnV2FPT0WU
HCE-4 NIC3[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMk[0N|kh|ryP M3P4TXNCVkeHUh?=
MZ2-MEL NUDvb5NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4SyVWlEPTB;MD6yPFU{PyEQvF2= M1TSSHNCVkeHUh?=
BL-41 NGri[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP3W5VKSzVyPUCuNlkyOjNizszN Mm\MV2FPT0WU
HUTU-80 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\qUIhKSzVyPUCuN|E1OiEQvF2= NFvSRWhUSU6JRWK=
LOXIMVI MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV70bGRZUUN3ME2wMlMyPTB|IN88US=> NYXC[o56W0GQR1XS
no-10 M4K5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImwU4NKSzVyPUCuN|E6OzFizszN M4LQU3NCVkeHUh?=
KARPAS-422 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q4WWlEPTB;MD6zN|k6PyEQvF2= MXvTRW5ITVJ?
SW684 NVnne3FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;CTWM2OD1yLkO0PVgh|ryP NXHrNIJmW0GQR1XS
SF126 M4HhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j4b2lEPTB;MD6zOVQyKM7:TR?= Ml3wV2FPT0WU
D-263MG NXTUWGtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nGNmlEPTB;MD6zOlIzPCEQvF2= NEmxZXhUSU6JRWK=
OVCAR-4 M2f1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7xWo1KSzVyPUCuN|c1OzNizszN NF7vWodUSU6JRWK=
BB49-HNC MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPYNIFKSzVyPUCuN|g2QTlizszN NVr6PIx2W0GQR1XS
ONS-76 NEPKeo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO1dnJKSzVyPUCuOFI6PTFizszN NYDOSFN1W0GQR1XS
MZ7-mel MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfs[JFKSzVyPUCuOFc6OTFizszN NH71V25USU6JRWK=
RCC10RGB NHXOc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O1TmlEPTB;MD60PVEyKM7:TR?= NVftd4tCW0GQR1XS
BOKU NF7ZXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H1V2lEPTB;MD60PVE{OyEQvF2= MX\TRW5ITVJ?
no-11 NGDZbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjYTVFCUUN3ME2wMlUxOjJ6IN88US=> NWPkS4NxW0GQR1XS
IST-SL2 NYe5W3lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\jcmlEPTB;MD61NFMxOiEQvF2= MXrTRW5ITVJ?
RKO M33yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHtbYF2UUN3ME2wMlUzQTZ4IN88US=> MorzV2FPT0WU
HT-144 Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;ZTWM2OD1yLkWzOlA6KM7:TR?= MYLTRW5ITVJ?
NCI-H446 M2LsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITqSllKSzVyPUCuOlI4PiEQvF2= M3v1RXNCVkeHUh?=
QIMR-WIL M2\ofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQTWM2OD1yLkewOlI6KM7:TR?= MWDTRW5ITVJ?
MHH-PREB-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwN{S0Olkh|ryP NYT2WoZ1W0GQR1XS
EW-16 NULveop3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;2cHZ{UUN3ME2wMlc3OTd6IN88US=> M1vReXNCVkeHUh?=
EW-24 M3f5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwN{ixOlUh|ryP MljXV2FPT0WU
LB373-MEL-D MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfaRVdJUUN3ME2wMlgzPTB6IN88US=> MknuV2FPT0WU
TE-9 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH5UFhKSzVyPUCuPFc2OzJizszN NGjUZXhUSU6JRWK=
A3-KAW MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHXdo9TUUN3ME2wMlk5PDV{IN88US=> NXLqcI9YW0GQR1XS
A101D NITz[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;BTWM2OD1zLkCzNFQ{KM7:TR?= NETsN4xUSU6JRWK=
OCUB-M Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvlRYxKSzVyPUGuNFQ1OTJizszN MWjTRW5ITVJ?
ES4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLaTWM2OD1zLkC1NVQ2KM7:TR?= NIn2UINUSU6JRWK=
TE-6 NH3DdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYewV4JEUUN3ME2xMlIyOjJ4IN88US=> MlXCV2FPT0WU
D-502MG NWjke3VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofYTWM2OD1zLkKzN|c3KM7:TR?= NXHuTW5wW0GQR1XS
KNS-42 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HaUGlEPTB;MT6yOFQyOiEQvF2= MmXYV2FPT0WU
SNU-C2B NEHWU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[5NmlEPTB;MT6zNFU5QSEQvF2= MV;TRW5ITVJ?
NCI-H1838 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XueWlEPTB;MT6zNFc{OyEQvF2= Mmi1V2FPT0WU
NKM-1 NYK1NVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwM{C4OVkh|ryP NGPwNldUSU6JRWK=
GI-1 NH3LR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwM{[yNkDPxE1? MUHTRW5ITVJ?
NB5 M3fyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwM{m4Nlch|ryP MUXTRW5ITVJ?
CAS-1 NEnIZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof1TWM2OD1zLkSwPVkzKM7:TR?= MmT1V2FPT0WU
HCE-T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW4PVZmUUN3ME2xMlU3PzF2IN88US=> Mn23V2FPT0WU
SBC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTHTWM2OD1zLkW3PVg1KM7:TR?= NFnjPXJUSU6JRWK=
JiyoyeP-2003 NHLjSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwN{O0OlYh|ryP M4XKcnNCVkeHUh?=
TE-5 NGjvZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7PTWM2OD1zLke5NVM6KM7:TR?= M2ryfnNCVkeHUh?=
CAN NWqzeZdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXvTWM2OD1zLkiyNlUzKM7:TR?= MULTRW5ITVJ?
SK-UT-1 NHPFS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPLTWM2OD1{LkG2Olk{KM7:TR?= MXXTRW5ITVJ?
JVM-2 NEfXRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXuPWZKSzVyPUKuN|YzQDRizszN M4fnVnNCVkeHUh?=
LB771-HNC M4LYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\4VlVIUUN3ME2yMlU4PTVzIN88US=> MkTUV2FPT0WU
NCCIT M{fJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf2T5g4UUN3ME2yMlg3PjF4IN88US=> NXfMTIxpW0GQR1XS
NCI-H2126 NVzZSZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwOEe1OVIh|ryP NHm2XFRUSU6JRWK=
Calu-6 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfjTWM2OD1|LkC1O|QyKM7:TR?= MXLTRW5ITVJ?
SK-LMS-1 NYLXWXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXrTWM2OD1|LkGxPFg3KM7:TR?= MkTlV2FPT0WU
ARH-77 NIjs[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITydo5KSzVyPUOuOFY6OTVizszN NF\jclRUSU6JRWK=
NB17 MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknWTWM2OD1|Lk[zPFQ4KM7:TR?= MnzTV2FPT0WU
A253 NWHPTnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHpWphJUUN3ME2zMlc{OjR4IN88US=> NX;3NVQ3W0GQR1XS
OPM-2 NH7uVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHMR5lJUUN3ME20MlI4Pjh3IN88US=> M4naNnNCVkeHUh?=
MV-4-11 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j6cGlEPTB;ND6zOlQ2PCEQvF2= NVfOfGVrW0GQR1XS
SR MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTRwNEm5OVQh|ryP MWLTRW5ITVJ?
KG-1 M{DKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[wUFBKSzVyPUSuOlA5PDVizszN MkjXV2FPT0WU
OCI-AML2 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTVwOE[xOVQh|ryP NWLDSZh{W0GQR1XS
D-247MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\FOGlEPTB;Nj6xNlUyQSEQvF2= Mn3VV2FPT0WU
DJM-1 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrBPJZKSzVyPU[uOFg2PThizszN NGHOPWZUSU6JRWK=
RPMI-6666 M4XBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\5SmlEPTB;Nz6yO|A3PyEQvF2= MorJV2FPT0WU
KARPAS-45 NWrxZm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTdwNUG2O|Eh|ryP NEmybopUSU6JRWK=
LP-1 NFnEbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTdwNUS3PFIh|ryP M{nyVHNCVkeHUh?=
RS4-11 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nQfGlEPTB;Nz62OVc5PyEQvF2= NHvEbotUSU6JRWK=
DU-4475 M2fmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITYU2hKSzVyPUiuNlE3PTJizszN NGP0bmZUSU6JRWK=
MONO-MAC-6 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X2R2lEPTB;OD6yO|A3PiEQvF2= M2DSOnNCVkeHUh?=
NCI-SNU-16 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3DTWM2OD16LkW2NVI5KM7:TR?= MnzUV2FPT0WU
SJSA-1 NULvOoNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPPdm5IUUN3ME24MlczQDB3IN88US=> M3XZcHNCVkeHUh?=
MMAC-SF NUTwXVFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvnTWM2OD16Lke5N|A4KM7:TR?= MXvTRW5ITVJ?
SK-NEP-1 M1fYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPrZ2JKSzVyPUiuPFkyPTVizszN M1ftWXNCVkeHUh?=
J-RT3-T3-5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjObJFKSzVyPUiuPVY2OjlizszN NFTIdZFUSU6JRWK=
SKM-1 MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\3S4VGUUN3ME25MlAyPzN2IN88US=> MnzQV2FPT0WU
LB2241-RCC NGHwe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLRdWo6UUN3ME25MlAzODF{IN88US=> MoLIV2FPT0WU
SIG-M5 M33xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\MTWM2OD17LkCyOFk{KM7:TR?= MWHTRW5ITVJ?
EVSA-T NFPHcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTlwMke3PVMh|ryP M{i3OXNCVkeHUh?=
GT3TKB M{\1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjPdpRYUUN3ME25MlM2PTR4IN88US=> NHTHS2VUSU6JRWK=
NB6 NHXzU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTNe4dMUUN3ME25MlkzOjV7IN88US=> MnfqV2FPT0WU
EHEB NEK2XJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO5UHVKSzVyPUGwMlA3PTZizszN M1Tld3NCVkeHUh?=
HEL MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7DTWM2OD1zMD60O|c3KM7:TR?= MV;TRW5ITVJ?
ALL-PO MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFyLke5N|gh|ryP M3;mdnNCVkeHUh?=
TGW NH7JcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLnN2xKSzVyPUGxMlI5OjhizszN MVjTRW5ITVJ?
BC-3 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHP[XlKSzVyPUGyMlEyOzhizszN NHfmU|ZUSU6JRWK=
IA-LM NGrDTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HTNGlEPTB;MUKuOFQ1PSEQvF2= MYXTRW5ITVJ?
UACC-257 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLFOodKSzVyPUGyMlkyQThizszN NVLUd2RMW0GQR1XS
KP-N-YS M{DQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnDNoc1UUN3ME2xNk46Ojh|IN88US=> MX\TRW5ITVJ?
Raji M1v1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF|Lke0PVch|ryP MX;TRW5ITVJ?
SF539 NGXXbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ezbWlEPTB;MUOuPFU2PyEQvF2= M{LBVnNCVkeHUh?=
DMS-153 NIPGdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF2LkCwNlgh|ryP Mlf6V2FPT0WU
L-540 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTaU2RKSzVyPUG1MlA3PzJizszN NIXv[ohUSU6JRWK=
MN-60 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33jVGlEPTB;MUWuNVk4QSEQvF2= M3z4ZnNCVkeHUh?=
RPMI-8866 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXoXZJYUUN3ME2xO{41PDV2IN88US=> NYTmcnBJW0GQR1XS
NCI-H510A NUC5XHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq2TWM2OD1zOT6zPVc{KM7:TR?= NV\KNIpMW0GQR1XS
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH62N4NKSzVyPUG5MlQ5PzdizszN M4TYT3NCVkeHUh?=
HAL-01 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfJR4E6UUN3ME2xPU44PTR|IN88US=> NFm3WHFUSU6JRWK=
NCI-H720 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XqU2lEPTB;MkCuNlc{OyEQvF2= M{nKRnNCVkeHUh?=
REH NH3CSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;STWM2OD1{MD62N|U4KM7:TR?= NHrN[GVUSU6JRWK=
KNS-81-FD MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ|LkG0OkDPxE1? MVfTRW5ITVJ?
HC-1 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTNNpJNUUN3ME2yOE42PTVzIN88US=> MU\TRW5ITVJ?
NCI-H2141 NWW5OlBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf3cIdKSzVyPUK0Mlc4PTRizszN NGnRZ3NUSU6JRWK=
MOLT-4 M3HETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ4Lk[3OVMh|ryP M4D5VXNCVkeHUh?=
OMC-1 NFS1dnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHJNFA6UUN3ME2yO{4yPDJ{IN88US=> NFz6dZlUSU6JRWK=
LC-1F M1iwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmewTWM2OD1{Nz6zNlQ2KM7:TR?= NVP5eGlHW0GQR1XS
NCI-H1304 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml23TWM2OD1{OD6xOlI5KM7:TR?= M3XxWXNCVkeHUh?=
BC-1 NGDwPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jqeGlEPTB;MkiuOlUyKM7:TR?= NHrm[mNUSU6JRWK=
NCI-H64 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfnTWM2OD1{OT62NlU{KM7:TR?= Mon0V2FPT0WU
MOLT-16 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj4dWxKSzVyPUK5MlYzQTJizszN NH60W|lUSU6JRWK=
U-87-MG MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLZR3BKSzVyPUOwMlc3PiEQvF2= MkXjV2FPT0WU
GAK MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjkO3BKSzVyPUOxMlI3QDZizszN M3myU3NCVkeHUh?=
ES8 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWxdHF2UUN3ME2zNk4yOjV{IN88US=> NGPyXHZUSU6JRWK=
HCC1599 NFvNUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTiTWM2OD1|Mj6zN|I2KM7:TR?= M{DiV3NCVkeHUh?=
EB-3 M4XncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P3S2lEPTB;M{SuN|EyPyEQvF2= MkHiV2FPT0WU
HCC1187 MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PLO2lEPTB;M{WuPFA2OiEQvF2= NWTxOmM3W0GQR1XS
SK-PN-DW M1fwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULzV2puUUN3ME2zOk4yQTR|IN88US=> M1PLbXNCVkeHUh?=
JVM-3 NXvGSnl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLZUJF6UUN3ME2zO{4zOzN6IN88US=> MmTjV2FPT0WU
HCC2157 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnRT3BMUUN3ME2zO{46QTR4IN88US=> MkHrV2FPT0WU
A4-Fuk M4ntXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLNTWM2OD1|OD6xNFA6KM7:TR?= MW\TRW5ITVJ?
COR-L279 M13RZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfyWpFKSzVyPUSwMlI5PTFizszN NUXkU5pYW0GQR1XS
DEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX6ZXU{UUN3ME20NU46ODh4IN88US=> M1;RXnNCVkeHUh?=
NCI-H1395 NITrSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\CWZpKSzVyPUSyMlAyPjNizszN MX;TRW5ITVJ?
MHH-NB-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHWzfmxKSzVyPUSzMlA5OThizszN NF;lPXlUSU6JRWK=
NCI-H2107 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;WTGlEPTB;NEOuOFg1PiEQvF2= MnjLV2FPT0WU
NEC8 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR2LkOzOkDPxE1? M{TyOHNCVkeHUh?=
COLO-684 NEDDZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTuTWM2OD12Nj6yNlU5KM7:TR?= M3XkeXNCVkeHUh?=
LS-411N M1\xWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi1XoZCUUN3ME20PE41PzR6IN88US=> M321PXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

- Collapse
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825
Smiles CC1=NC(=CC(=N1)N2CCN(CCO)CC2)NC3=NC=C(S3)C(=O)NC4=C(Cl)C=CC=C4C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Suspended Drug: Dasatinib + Quercetin Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic February 14 2020 Phase 1|Phase 2
NCT04155411 Recruiting Drug: Dasatinib Dasatinib|BCR-ABL|Chronic Myeloid Leukemia Shenzhen Second People''s Hospital December 1 2019 Phase 4
NCT04115059 Recruiting Drug: Dasatinib Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 4 2019 Phase 1
NCT03318770 Not yet recruiting Drug: Dasatinib and blinatumomab Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Drug: Dasatinib Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID